×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. We are committed to safeguarding your information and ensuring the highest standards of data protection. Your trust and privacy are of utmost importance to us.

CANVAS Program

  1018 Views

Dr Bruce Neal, UK    01 February 2018

  1. Inclusion criteria: Patients with type 2 diabetes - HbA1c ≥7.0% to ≤10.5%; eGFR ≥30 mL/min/1.73 m2; age ≥30 years and history of prior CV event; OR age ≥50 years with ≥2 CV risk factors (diabetes duration ≥10 years, SBP >140 mmHg on ≥1 medication, current smoker, micro- or macroalbuminuria or HDL-C <1 mmol/L).
  2. The CANVAS Program met its primary objective of demonstrating the CV safety and efficacy of canagliflozin.
  3. The data suggest a favorable benefit/risk profile with canagliflozin treatment in many patients with type 2 diabetes and high CV risk.
  4. During the discussion/questions session, the risk of amputation and fractures was discussed among the audience members and the speaker, and it was concluded that there has been no increased risk of fractures or amputations in patients in real clinical practice.
  5. The increased risk of amputation may be there only in patients who have a history of amputation.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.